Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT03427996
Recruiting Observational

Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice

NCT03427996 · tracked via the Priya Life Science South Korea tracker
Sponsor
Seung-Jung Park
Phase
Observational
Started
2018-09-04
Last updated
2026-01-02

Condition(s) studied

Atherosclerosis, CoronaryCoronary Stenosis

Investigational drug(s) / intervention(s)

Rotational atherectomy

Rotational atherectomy: Percutaneous coronary intervention with rotational atherectomy

Study summary

This study evaluates the effectiveness and safety rotational atherectomy in routine clinical practice.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients ≥ 19 years old * Patients who received rotational atherectomy * The patient or guardian agrees to the study protocol and the schedule of clinical follow-up and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site. Exclusion Criteria: * Life expectancy \<1y

Primary outcome measure(s)

  • Target vessel failure (TVF) — 1 year
    Target vessel failure (TVF) composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target Vessel Revascularization (TVR) at 12 months after the procedure.

Trial sites (8)

FacilityCityRegionStatus
Soon Chun Hyang University Hospital Bucheon Bucheon-si South Korea Recruiting
Daegu Catholic University Medical Center Daegu South Korea Recruiting
Chungnam National University Hospital Daejeon South Korea Terminated
The Catholic University of Korea, Daejeon ST. Mary's Hospital Daejeon South Korea Withdrawn
Chonnam National University Hospital Gwangju South Korea Not Yet Recruiting
Inje University Pusan Paik Hospital Pusan South Korea Terminated
Bundang CHA Hospital Seongnam South Korea Terminated
Asan Medical Center Seoul South Korea Recruiting

More Seung-Jung Park trials in South Korea

Study of the Natural History of FFR Guided Percutaneous Coronary Intervention Recruiting
Observational Study for Left Main Disease Treatment Recruiting
Asan Multivessel Registry Recruiting
IRIS-Onyx Cohort in the IRIS-DES Registry Active, not recruiting
Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease Recruiting

Other trials for the same condition

Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease Active, not recruiting
IRIS- DESyne X2 in the IRIS-DES Registry Recruiting
Asan Medical Center Myocardial Infarction Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03427996 on ClinicalTrials.gov ↗ ← All trials in South Korea